A Study to Assess Anktiva in Patients With Long Covid
Phase 2
20
about 1 year
18–70
1 site in CA
What this study is about
This trial is testing the safety and tolerability of a treatment called Anktiva in people with Long COVID. Participants will receive up to two doses of Anktiva, along with follow-up exams and tests.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take N-803 (IL-15 Superagonist)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Antineoplastic Agent [TC] (Cytokine Receptor Superfamily Interactions)
Primary: Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration., Incidence of serious adverse events (SAEs) through 30 days post final study drug administration., Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.
Secondary: Change in other assessments (eg, EuroQoL Quality of Life) from baseline, intervention 2, FU2.3 (2 weeks after last NAI administration), FU2.5, and EOS., Change in patient-reported outcomes (PROs) PROMIS-29 score from Baseline to FU2.5 (45 days following last NAI administration).